Kimball Electronics, Inc. announced financial results for the fourth quarter and full fiscal year ended June 30, 2025. For Q4 FY25, net sales were $380.5 million, a 12% decrease year-over-year, while adjusted diluted EPS was $0.34. Adjusted operating income for the quarter was $19.6 million, or 5.2% of net sales.
For the full fiscal year 2025, net sales totaled $1.49 billion, a 13% decrease from the prior year, and adjusted diluted EPS was $1.12. The company achieved its sixth consecutive quarter of positive cash flow from operating activities, generating $183.9 million for the full fiscal year. Borrowings on credit facilities were reduced to $147.05 million at June 30, 2025, and cash conversion days improved to 85 days in Q4.
Kimball Electronics provided its guidance for fiscal year 2026, anticipating modest top-line growth in its medical and industrial businesses. This growth is expected to be offset by a decline in the automotive segment due to the full-year impact from the loss of a braking program in Reynosa. Margins are estimated to be in line with fiscal year 2025, with capital expenditures heavily weighted towards the new Indianapolis medical facility.
Management highlighted significant progress in fiscal 2025, including a record number of new business wins, adjustments to the cost structure, and an intensified focus on the medical Contract Manufacturing Organization (CMO) strategy. The company's balance sheet is positioned for competitive strength, providing liquidity for opportunistic investments and future growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.